On March 31, 2022 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that Dr. Anna Berkenblit, Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel discussion at the upcoming Canaccord Genuity Horizons in Oncology Virtual Conference (Press release, ImmunoGen, MAR 31, 2022, View Source [SID1234611295]). The panel is scheduled for April 14, 2022 from 8:00 – 8:50am ET .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the panel will be accessible through the "Investors and Media" section of the Company’s website, www.immunogen.com. Following the live webcast, a replay will be available at the same location.